Financial Summary for Q3 FY March 2026 [Japanese GAAP] (Consolidated)

Overview of Business Performance

During the consolidated cumulative period of Q3 FY March 2026, net sales were 487.305 billion yen, a 1.7% increase YoY. Operating income was 26.747 billion yen (20.5% increase), ordinary income was 17.608 billion yen (25.7% increase), and net income attributable to owners of the parent for the quarter was 16.684 billion yen (153.0% increase), achieving growth in both revenue and profits. The main factors for profit growth include gain on step acquisitions due to acquisition of consolidated subsidiaries, gains on sales of fixed assets, and foreign exchange gains. By segment, the medical-related business posted net sales of 387.975 billion yen (3.7% YoY increase) and operating income of 3.7521 billion yen (3.1% YoY increase), showing steady results. The pharmaceutical-related business recorded net sales of 58.979 billion yen (0.2% YoY decrease) but improved operating income to 8.811 billion yen (35.8% YoY increase). The pharma packaging business saw a decline with net sales of 39.455 billion yen (12.5% decrease) and an operating loss of 1.477 billion yen, resulting in both revenue and profit decline.

Financial Position and Outlook

As of the end of Q3, total assets stood at 1.199895 trillion yen, an increase of 29.33 billion yen compared to the end of the previous fiscal year. Total liabilities increased by 26.192 billion yen to 885.135 billion yen, and the equity ratio was 21.3%, a decrease of 0.3 points YoY. There were no significant changes in the number of shares issued or treasury stock. The consolidated earnings forecast for the full fiscal year ending March 2026 remains unchanged from the previous announcement; net sales are projected at 677 billion yen (5.0% YoY increase), operating income at 37 billion yen (39.1% YoY increase), and net income attributable to owners of the parent at 12.95 billion yen (153.2% YoY increase).